ClinicalTrials.gg
CompletedNCT05170074Updated Oct 23, 2026

Post-market Clinical Follow-up of the SRS Implant

An observational study in Pelvic Organ Prolapse, sponsored by pfm medical gmbh. Completed at 6 sites in Germany. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by pfm medical gmbh · Observational

How we know

Updated Oct 23, 2026Now CompletedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
97
Ages
21 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Pelvic Organ Prolapse with a site in Germany — 4 open to participants now, 6 under way, none of them phase 3. Pelvic Organ Prolapse · Germany.

Enrollment
9th of 14
97 · median 113
Started
2022
with 2 others
Observational
14 of 19
2 open now
Registered
13th of 19
by date
Lead sponsor
1 of 19
pfm medical gmbh

Among the 19 studies in Pelvic Organ Prolapse with a site in Germany, this one is the 9th largest by enrollment of the 14 observational ones that give a count, is one of 3 that started in 2022, is one of 14 observational ones, and was the 13th registered.

Pelvic Organ Prolapse

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

Browse Pelvic Organ Prolapse studies →

Open to participants now

4 of the 19 studies in Pelvic Organ Prolapse with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.

This study: 21 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pelvic Organ Prolapse with a site in Germany, or all of them as a file.
02

Study summary

National, multicentre observational study on surgical reconstruction of the anterior and apical compartment of the pelvic floor with an SRS implant

Read the detailed description

National, multicentre, prospective observational study on surgical reconstruction of the anterior and apical compartment in seven clinical centres in Germany to obtain post-market information on the SRS implant with a follow-up of 24 months. Patient reported satisfaction (measured by P QoL, Prolapse Quality of Life Questionnaire), anatomic outcome (measured by the POP-Q, Pelvic Organ Prolapse Quantification system) and the rate of complications (measured by adverse events during the study period) are focused.

03

Conditions studied

  • Pelvic Organ Prolapse

Browse trials for

Keywords

  • SRS Implant
  • Quality of Life
  • Pelvic Organ Prolapse
  • Surgical Reconstruction
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Women with a symptomatic anterior vaginal wall prolapse with/without apex/uterine prolapse ≥ stage II (according to POP-Q system), transvaginal SRS implantation for pelvic organ prolapse surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women with a symptomatic anterior vaginal wall prolapse with/without apex/uterine prolapse ≥ stage II (according to POP-Q system). This applies to primary as well as recurrent intervention.
  2. Age ≥ 21 years.
  3. Patient is mentally able to understand the nature, aims, or possible consequences of the PMCF study.
  4. Patient information has been provided and written consent exists.

Exclusion criteria

Exclusion Criteria:

  1. according to the manufacturer's instructions for use.
  2. Patient with previous urogynaecological surgeries with alloplastic material.
  3. Patient with radiological treatment in the pelvic floor.
  4. Patient is institutionalised by court or official order (MPDG §27).
  5. Participation in another interventional study concerning pelvic floor reconstruction.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
97 participants (actual)
Patient registry
No

Groups and cohorts

  • SRS implant

    Surgical reconstruction of the anterior and apical compartment of the pelvic floor with an SRS implant

06

What researchers measure

Primary outcomes

  1. Patient´s Quality of Life

    Evaluation of changes in quality of life twelve months after implantation of the SRS implant compared to baseline. Quality of Life was assessed by the P-QOL (Prolapse Quality of Life Questionnaire). The P-QOL yields a domain score in the range from zero to 100, wheras a score of zero is the best.

    Time frame: 12 months

07

Study locations

6 sites
  • Universitätsklinikum Augsburg
    Augsburg, 86156, Germany
  • Evangelisches Krankenhaus Hagen-Haspe
    Hagen, 58135, Germany
  • Asklepios Klinik Altona
    Hamburg, 22763, Germany
  • Städtisches Krankenhaus Kiel
    Kiel, 24116, Germany
  • Marienhaus Klinikum Hetzelstift Neustadt/Weinstraße
    Neustadt, 67434, Germany
  • Klinikum Oberlausitzer Bergland gGmbH
    Zittau, 02763, Germany
08

References and documents

Publications

  • Levy G, Padoa A, Marcus N, Beck A, Fekete Z, Cervigni M. Anchorless implant for the treatment of advanced anterior and apical vaginal prolapse - Medium term follow up. Eur J Obstet Gynecol Reprod Biol. 2020 Mar;246:55-59. doi: 10.1016/j.ejogrb.2020.01.005. Epub 2020 Jan 9. PubMed 31954369 ↗
  • Levy G, Padoa A, Fekete Z, Bartfai G, Pajor L, Cervigni M. Self-retaining support implant: an anchorless system for the treatment of pelvic organ prolapse-2-year follow-up. Int Urogynecol J. 2018 May;29(5):709-714. doi: 10.1007/s00192-017-3415-3. Epub 2017 Jul 14. PubMed 28710613 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Sep 2025, 41 months.

Of 61 observational studies under Pelvic Organ Prolapse, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2021
First posted
Dec 27, 2021
StartActual
Apr 7, 2022
Primary completionActual
Sep 24, 2025
CompletionActual
Sep 9, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 23, 2026
Sites
1 site removed
Show 1 removed
  • Heilig Geist-Hospital · Bensheim, Germany
Oct 23, 2026
Enrollment
175 (estimated)→97 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Completed
    1 site removed
    Show 1 removed
    • Heilig Geist-Hospital · Bensheim, Germany
    Enrollment 175 (estimated)→97 (actual)
    + 5 other changes: verification date, date precision, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05170074
Lead sponsor
pfm medical gmbh
Responsible party
Sponsor
First posted
Dec 27, 2021
Start date
Apr 7, 2022
Primary completion
Sep 24, 2025
Completion
Sep 9, 2026
Last update
Oct 23, 2026

Study contacts

Tina Cadenbach-Blome, Dr. med.
principal investigator · OBERSCHWABENKLINIK gGmbH Westallgäuklinikum

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion